Response to rituximab treatment at 12 months (secondary endpoint)
| Definition of improvement | Improved/treated, n (%) | 95% CI |
| Patients’ improvement at 12 months | ||
| ≥2 MRC or 1 INCAT or 4 RODS centile points | 13/14 (92.9) | 66.1 to 99.8 |
| ≥4 MRC or 1 INCAT or 4 RODS centile points | 10/14 (71.4) | 41.9 to 91.6 |
| Patients’ improvement at 12 months in each score (including missing data from three patients) | ||
| Definition of improvement | Improved/treated, n (%) | 95% CI |
| ≥2 MRC or 1 INCAT or 4 RODS centile points | 15/17 (88.2) | 63.6 to 98.5 |
| ≥4 MRC or 1 INCAT or 4 RODS centile points | 12/17 (70.6) | 44.0 to 89.7 |
| Patients’ improvement at 12 months in each score | ||
| Definition of improvement | Improved/treated, n (%) | |
| INCAT<1 point | 7/14 (50.0) | |
| RODS>4 centile points | 7/14 (50.0) | |
| MRC>2 points | 11/14 (78.6) | |
| MRC>4 points | 5/14 (35.7) | |
| ≥20% improved in at least one among MCV, DL, amplitude or duration of CMAP in at least motor 2 nerves | 7/13 (53.9)* | |
| ≥MCID threshold in at least one among mean CMAP duration, mean MCV, CB, CMAP duration of the most affected motor nerve30 | 7/13 (53.9)* | |
*Not available in two patients.
CB, conduction block; CMAP, compound motor action potential; DL, distal latency; INCAT, Inflammatory Neuropathy Cause and Treatment Disability Scale; MCID, minimum clinical important difference; MCV, motor conduction velocity; MRC, Medical Research Council; RODS, Rasch Overall Disability Scale.